Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 72 entries
View as:

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03860948 Org: User:
Start: 04/16/19 End: 05/14/19 Due: 05/14/20

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02897479 Org: User:
Start: 12/31/16 End: 12/30/21 Due: 12/30/22

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02966171 Org: User:
Start: 01/31/17 End: 08/23/18 Due: 08/23/19

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01645215 Org: User:
Start: 01/31/11 End: 10/31/12 Due: 10/31/13

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01985555 Org: User:
Start: 05/31/13 End: 04/30/19 Due: 04/30/20

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02503033 Org: User:
Start: 11/30/15 End: 03/31/21 Due: 03/31/22

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02590952 Org: User:
Start: 10/31/11 End: 04/30/19 Due: 04/30/20

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02976116 Org: User:
Start: 12/31/16 End: 06/28/19 Due: 06/28/20

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02966821 Org: User:
Start: 01/03/17 End: 11/30/18 Due: 11/30/19

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01773018 Org: User:
Start: 02/29/12 End: 05/31/16 Due: 05/31/17

HMPL-813 in Treating Patients With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT03231501 Org: User:
Start: 01/26/18 End: 08/31/20 Due: 08/31/21

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01955304 Org: User:
Start: 06/30/12 End: 12/31/12 Due: 12/31/13

HMPL-453 in Advanced Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT04290325 Org: User:
Start: 12/30/19 End: 03/17/23 Due: 03/17/24

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT04272957 Org: User:
Start: 05/14/20 End: 12/30/22 Due: 12/30/23

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Phase: N/A Priority: Normal
NCT ID: NCT02314819 Org: User:
Start: 12/31/14 End: 01/17/17 Due: 01/17/18

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03251378 Org: User:
Start: 12/11/17 End: 03/30/23 Due: 03/30/24

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT02601248 Org: User:
Start: 10/31/12 End: 05/31/16 Due: 05/31/17

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers

Phase: N/A Priority: Normal
NCT ID: NCT03483259 Org: User:
Start: 04/02/18 End: 05/18/18 Due: 05/18/19

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT01805791 Org: User:
Start: 03/31/13 End: 10/31/14 Due: 10/31/15

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT02601274 Org: User:
Start: 04/30/15 End: 12/31/18 Due: 12/31/19

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02267967 Org: User:
Start: 10/31/14 End: 08/23/17 Due: 08/23/18

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Phase: N/A Priority: Normal
NCT ID: NCT02320409 Org: User:
Start: 12/31/14 End: 04/30/15 Due: 04/30/16

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03873532 Org: User:
Start: 07/10/18 End: 03/31/22 Due: 03/31/23

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Phase: N/A Priority: Normal
NCT ID: NCT04645940 Org: User:
Start: 09/24/20 End: 11/18/20 Due: 11/18/21

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04372394 Org: User:
Start: 08/14/20 End: 03/02/21 Due: 03/02/22